Respiratory antivirals are a class of medications that are used to treat viral infections of the respiratory system. Most viral infections resolve spontaneously in immunocompetent individuals. Antiviral therapy aims to minimize symptoms and infectivity as well as to shorten the duration of illness. These drugs act by arresting the viral replication cycle at various stages.
MARKET DYNAMICS
Factors driving the growth of the respiratory antivirals market are the growing incidences of respiratory infections, coupled with technological advancements such as use of nanotechnology in virology. However, the uncertainties in the regulatory guidelines is expected to hamper the growth of the market. Moreover, increasing demand for quality healthcare and favorable policies for treatment and prevention of respiratory viral diseases is anticipated to boost the market growth.
MARKET SCOPE
The "Respiratory Antivirals Market Analysis to 2028" is a specialized and in-depth study of the healthcare industry with a special focus on the global market trend analysis. The report aims to provide an overview of respiratory antivirals market with detailed market segmentation by disease type and drug class. The respiratory antivirals market is expected to witness high growth during the forecast period. The report provides key statistics on the market status of the leading players in respiratory antivirals market and offers key trends and opportunities in the market.
MARKET SEGMENTATION
The respiratory antivirals market is segmented on the basis of disease type and drug class. Based on disease type, the market is segmented as influenza, pneumonia, bronchiolitis, croup, measles, upper respiratory tract infections (URTIS), and others. On the basis of drug class, the market is categorized as neuraminidase inhibitors, ion channel blockers, nucleoside analogs, and fusion protein inhibitors. Neuraminidase inhibitors divided as zanamivir and oseltamivir. Ion channel blockers divided as rimantadine and amantadine. Nucleoside analogs divided as ribavirin and aciclovir. Fusion protein inhibitors divided as pavilizumab.
REGIONAL FRAMEWORK
The report provides a detailed overview of the industry including both qualitative and quantitative information. It provides overview and forecast of the respiratory antivirals market based on various segments. It also provides market size and forecast estimates from year 2020 to 2028 with respect to five major regions, namely; North America, Europe, Asia-Pacific (APAC), Middle East and Africa (MEA) and South & Central America. The respiratory antivirals market by each region is later sub-segmented by respective countries and segments. The report covers analysis and forecast of 18 countries globally along with current trend and opportunities prevailing in the region.
The report analyzes factors affecting respiratory antivirals market from both demand and supply side and further evaluates market dynamics affecting the market during forecast period i.e., drivers, restraints, opportunities, and future trend. The report also provides exhaustive PEST analysis for all five regions namely; North America, Europe, APAC, MEA and South & Central America after evaluating political, economic, social and technological factors effecting the respiratory antivirals market in these regions.
MARKET PLAYERS
The report covers key developments in the respiratory antivirals market as organic and inorganic growth strategies. Various companies are focusing on organic growth strategies such as product launches, product approvals and others such as patents and events. Inorganic growth strategies witnessed in the market were acquisitions, and partnership & collaborations. These activities have paved way for expansion of business and customer base of market players. The market players from respiratory antivirals market are anticipated to have lucrative growth opportunities in the future with the rising demand for respiratory antivirals in the global market. Below mentioned is the list of few companies engaged in the respiratory antivirals market.
The report also includes the profiles of key players in respiratory antivirals market along with their SWOT analysis and market strategies. In addition, the report focuses on leading industry players with information such as company profiles, components and services offered, financial information of last 3 years, key development in past five years.
- Takeda Pharmaceutical Company Limited
- Pfizer, Inc.
- GlaxoSmithKline plc
- Mylan Inc.
- Merck & Co., Inc.
- AstraZeneca plc.
- F. Hoffmann-La Roche Ltd.
- Novartis AG
- Teva Pharmaceutical Industries Ltd.
- Sun Pharmaceutical Industries Ltd.
The Insight Partner's dedicated research and analysis team consists of experienced professionals with advanced statistical expertise and offers various customization options in the existing study.